{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:12:56Z","timestamp":1788441176900,"version":"build-2803163510"},"reference-count":120,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Arrhythmogenic cardiomyopathy (ACM) is a hereditary myocardial disorder characterized by progressive replacement of ventricular myocardium with fibro-fatty tissue, leading to life-threatening ventricular arrhythmias and heart failure. Historically, management has focused on arrhythmia suppression and prevention of sudden cardiac death (SCD). However, recent advances in understanding disease mechanisms have redefined ACM as a structural\u2013metabolic cardiomyopathy. Central to this evolving paradigm is the \u201cadipogenic switch\u201d, driven by desmosomal dysfunction, impaired Wnt\/\u03b2-catenin signaling, and activation of the peroxisome proliferator-activated receptor gamma (PPAR\u03b3) pathway. Emerging evidence highlights the critical role of metabolic dysregulation, specifically the oxidized low-density lipoprotein (oxLDL)\/cluster of differentiation 36 (CD36)\/PPAR\u03b3 axis, in driving disease progression. Elevated oxLDL levels correlate with greater phenotypic severity, increased ventricular fat infiltration, and a higher arrhythmic risk. Translational models demonstrate that high-fat diets exacerbate the ACM phenotype, whereas lipid-lowering interventions, particularly statins, show potential to arrest fibro-fatty remodeling. In addition to the primary inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase associated with statins, these medications exert pleiotropic effects, including attenuation of systemic inflammation, stabilization of the intercalated disc via Rho GTPase modulation, and reduction of oxidative stress. Clinical data from non-ischemic dilated cardiomyopathy (NIDCM) suggest that lipophilic statins such as atorvastatin, may confer significant mortality and antiarrhythmic benefits by stabilizing the myocardial electrical substrate. The ongoing SEARCH trial (NCT06922994) represents a landmark effort to translate these insights into clinical practice. Using high-dose atorvastatin and sensitive primary endpoints, such as right ventricular free wall longitudinal strain, this study aimed to determine whether lipid-lowering therapy can function as a true disease-modifying intervention in ACM. The integration of lipid-lowering agents into the therapeutic armamentarium for ACM could enable a transition toward precision medicine, contingent upon successful clinical validation. If clinical trials confirm the efficacy of these agents in slowing myocardial substrate decay, this approach could redefine the management of ACM, including the use of targeted molecular strategies to preserve myocardial identity and electrical stability.<\/jats:p>","DOI":"10.31083\/rcm51364","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:17:46Z","timestamp":1788437866000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipid Metabolism as a Therapeutic Target in Arrhythmogenic Cardiomyopathy: Emerging Therapeutic Implications of Lipid-Lowering Therapy"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2895-4219","authenticated-orcid":true,"given":"Nicol\u00f2","family":"Pasini","sequence":"first","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1412-4747","authenticated-orcid":true,"given":"Federico","family":"Barocelli","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bettella","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ristagno","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Santoro","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"},{"name":"Cardiology Division, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Canu","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Crocamo","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo Luca","family":"Gurgoglione","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Torlai","family":"Triglia","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Russo","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Guidorossi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gaibazzi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Notarangelo","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Gonzi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-6262","authenticated-orcid":true,"given":"Giampaolo","family":"Niccoli","sequence":"additional","affiliation":[{"name":"Cardiology Division, Parma University Hospital, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Corrado D, Basso C, Judge DP. Arrhythmogenic Cardiomyopathy. Circulation Research. 2017; 121: 784\u2013802.","DOI":"10.1161\/CIRCRESAHA.117.309345"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hoorntje ET, Te Rijdt WP, James CA, Pilichou K, Basso C, Judge DP, et al. Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovascular Research. 2017; 113: 1521\u20131531.","DOI":"10.1093\/cvr\/cvx150"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Migliore F, Mattesi G, Zorzi A, Bauce B, Rigato I, Corrado D, et al. Arrhythmogenic Cardiomyopathy-Current Treatment and Future Options. Journal of Clinical Medicine. 2021; 10: 2750.","DOI":"10.3390\/jcm10132750"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bennett RG, Haqqani HM, Berruezo A, Della Bella P, Marchlinski FE, Hsu CJ, et al. Arrhythmogenic Cardiomyopathy in 2018-2019: ARVC\/ALVC or Both? Heart, Lung & Circulation. 2019; 28: 164\u2013177.","DOI":"10.1016\/j.hlc.2018.10.013"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari MD, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. International Journal of Cardiology. 2020; 319: 106\u2013114.","DOI":"10.1016\/j.ijcard.2020.06.005"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the task force criteria. Circulation. 2010; 121: 1533\u20131541.","DOI":"10.1161\/CIRCULATIONAHA.108.840827"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Corrado D, Anastasakis A, Basso C, Bauce B, Blomstr\u00f6m-Lundqvist C, Bucciarelli-Ducci C, et al. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. International Journal of Cardiology. 2024; 395: 131447.","DOI":"10.1016\/j.ijcard.2023.131447"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Barocelli F, Pasini N, Bettella A, Crocamo A, Ambrosini E, Gurgoglione FL, et al. Arrhythmogenic Cardiomyopathy and Biomarkers: A Promising Perspective? Journal of Clinical Medicine. 2025; 14: 7046.","DOI":"10.3390\/jcm14197046"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Elliott PM, Anastasakis A, Asimaki A, Basso C, Bauce B, Brooke MA, et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure. 2019; 21: 955\u2013964.","DOI":"10.1002\/ejhf.1534"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Haugaa KH, Haland TF, Leren IS, Saberniak J, Edvardsen T. Arrhythmogenic right ventricular cardiomyopathy, clinical manifestations, and diagnosis. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2016; 18: 965\u2013972.","DOI":"10.1093\/europace\/euv340"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, et al. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy-an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal. Cardiovascular Imaging. 2017; 18: 237\u2013253.","DOI":"10.1093\/ehjci\/jew229"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Muller SA, Bertoli G, Wang J, Gasperetti A, Cox MGPJ, Calkins H, et al. Arrhythmogenic Cardiomyopathy: Towards Genotype Based Diagnoses and Management. Journal of Cardiovascular Electrophysiology. 2025; 36: 2662\u20132670.","DOI":"10.1111\/jce.16519"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"van der Voorn SM, Te Riele ASJM, Basso C, Calkins H, Remme CA, van Veen TAB. Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy. Cardiovascular Research. 2020; 116: 1571\u20131584.","DOI":"10.1093\/cvr\/cvaa084"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Austin KM, Trembley MA, Chandler SF, Sanders SP, Saffitz JE, Abrams DJ, et al. Molecular mechanisms of arrhythmogenic cardiomyopathy. Nature Reviews. Cardiology. 2019; 16: 519\u2013537.","DOI":"10.1038\/s41569-019-0200-7"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Lipshultz SE, Law YM, Asante-Korang A, Austin ED, Dipchand AI, Everitt MD, et al. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. Circulation. 2019; 140: e9\u2013e68.","DOI":"10.1161\/CIR.0000000000000682"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Calkins H, Corrado D, Marcus F. Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2017; 136: 2068\u20132082.","DOI":"10.1161\/CIRCULATIONAHA.117.030792"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Gupta R, Tichnell C, Murray B, Rizzo S, Te Riele A, Tandri H, et al. Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia\/Cardiomyopathy. The American Journal of Cardiology. 2017; 120: 111\u2013117.","DOI":"10.1016\/j.amjcard.2017.03.251"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Smedsrud MK, Chivulescu M, Fors\u00e5 MI, Castrini I, Aabel EW, Rootwelt-Norberg C, et al. Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy. European Heart Journal. 2022; 43: 4694\u20134703.","DOI":"10.1093\/eurheartj\/ehac485"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Chandra N, Bastiaenen R, Papadakis M, Sharma S. Sudden cardiac death in young athletes: practical challenges and diagnostic dilemmas. Journal of the American College of Cardiology. 2013; 61: 1027\u20131040.","DOI":"10.1016\/j.jacc.2012.08.1032"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019; 16: e301\u2013e372.","DOI":"10.1016\/j.hrthm.2019.05.007"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Stevens TL, Wallace MJ, Refaey ME, Roberts JD, Koenig SN, Mohler PJ. Arrhythmogenic Cardiomyopathy: Molecular Insights for Improved Therapeutic Design. Journal of Cardiovascular Development and Disease. 2020; 7: 21.","DOI":"10.3390\/jcdd7020021"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kohela A, van Rooij E. Fibro-fatty remodelling in arrhythmogenic cardiomyopathy. Basic Research in Cardiology. 2022; 117: 22.","DOI":"10.1007\/s00395-022-00929-4"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Chen SN, Gurha P, Lombardi R, Ruggiero A, Willerson JT, Marian AJ. The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circulation Research. 2014; 114: 454\u2013468.","DOI":"10.1161\/CIRCRESAHA.114.302810"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Prior D, La Gerche A. Exercise and Arrhythmogenic Right Ventricular Cardiomyopathy. Heart, Lung & Circulation. 2020; 29: 547\u2013555.","DOI":"10.1016\/j.hlc.2019.12.007"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Tram\u00e8r L, Saguner AM, Beltrami FG, James CA, Calkins H, Duru F. Gene-elusive arrhythmogenic cardiomyopathy: Roles of sports, inflammation, and beyond. Heart Rhythm. 2025.  (in press)","DOI":"10.1016\/j.hrthm.2025.09.048"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, et al. Suppression of canonical Wnt\/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. The Journal of Clinical Investigation. 2006; 116: 2012\u20132021.","DOI":"10.1172\/JCI27751"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Stadiotti I, Catto V, Casella M, Tondo C, Pompilio G, Sommariva E. Arrhythmogenic Cardiomyopathy: the Guilty Party in Adipogenesis. Journal of Cardiovascular Translational Research. 2017; 10: 446\u2013454.","DOI":"10.1007\/s12265-017-9767-8"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Tsui H, Han SJ, van Rooij E. Oxidized low-density lipoproteins as a novel risk factor and therapeutic target for ACM. EMBO Molecular Medicine. 2021; 13: e14789.","DOI":"10.15252\/emmm.202114789"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Sommariva E, Stadiotti I, Casella M, Catto V, Dello Russo A, Carbucicchio C, et al. Oxidized LDL-dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy. EMBO Molecular Medicine. 2021; 13: e14365.","DOI":"10.15252\/emmm.202114365"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. The Journal of Biological Chemistry. 2000; 275: 12633\u201312638.","DOI":"10.1074\/jbc.275.17.12633"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL. LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation. Journal of the American College of Cardiology. 2017; 69: 2759\u20132768.","DOI":"10.1016\/j.jacc.2017.04.010"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Li YB, Zhang QH, Chen Z, He ZJ, Yi GH. Oxidized low-density lipoprotein attenuated desmoglein 1 and desmocollin 2 expression via LOX-1\/Ca(2+)\/PKC-\u03b2 signal in human umbilical vein endothelial cells. Biochemical and Biophysical Research Communications. 2015; 468: 380\u2013386.","DOI":"10.1016\/j.bbrc.2015.10.079"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Villa M, Cerda-Opazo P, Jimenez-Gallegos D, Garrido-Moreno V, Chiong M, Quest AF, et al. Pro-fibrotic effect of oxidized LDL in cardiac myofibroblasts. Biochemical and Biophysical Research Communications. 2020; 524: 696\u2013701.","DOI":"10.1016\/j.bbrc.2020.01.156"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Jostarndt K, Rubic T, Kuhn H, Anthosen MW, Andera L, Gellert N, et al. Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-gamma-dependent way. Biochemical Pharmacology. 2004; 67: 841\u2013854.","DOI":"10.1016\/j.bcp.2003.09.041"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Orgil BO, Spaulding MS, Smith HP, Baba Z, Alberson NR, Batsaikhan E, et al. Transmembrane Protein 43: Molecular and Pathogenetic Implications in Arrhythmogenic Cardiomyopathy and Various Other Diseases. International Journal of Molecular Sciences. 2025; 26: 6856.","DOI":"10.3390\/ijms26146856"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Akdis D, Weidmann L, Nanni P, Gaertner A, Milting H, Bode P, et al. Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy. ESC Heart Failure. 2025; 12: 4419\u20134430.","DOI":"10.1002\/ehf2.70013"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"de la Gu\u00eda-Galipienso F, Ugedo-Alzaga K, Grazioli G, Quesada-Ocete FJ, Feliu-Rey E, Perez MV, et al. Arrhythmogenic Cardiomyopathy and Athletes: A Dangerous Relationship. Current Problems in Cardiology. 2023; 48: 101799.","DOI":"10.1016\/j.cpcardiol.2023.101799"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Asatryan B, Asimaki A, Landstrom AP, Khanji MY, Odening KE, Cooper LT, et al. Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review. Circulation. 2021; 144: 1646\u20131655.","DOI":"10.1161\/CIRCULATIONAHA.121.055890"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Calabrese F, Basso C, Carturan E, Valente M, Thiene G. Arrhythmogenic right ventricular cardiomyopathy\/dysplasia: is there a role for viruses? Cardiovascular Pathology: the Official Journal of the Society for Cardiovascular Pathology. 2006; 15: 11\u201317.","DOI":"10.1016\/j.carpath.2005.10.004"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Mahdavi M, Hosseini L, Mozzaffari K, Zadehbagheri F, Rezaeian N. A challenging case of arrhythmogenic right ventricular cardiomyopathy presenting as fulminant myocarditis. Oxford Medical Case Reports. 2021; 2021: omab013.","DOI":"10.1093\/omcr\/omab013"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Bassetto G, Angriman F, Gava CPLD, Paldino A, Perotto M, Bordignon L, et al. Hot Phases Cardiomyopathy: Pathophysiology, Diagnostic Challenges, and Emerging Therapies. Current Cardiology Reports. 2025; 27: 11.","DOI":"10.1007\/s11886-024-02168-6"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"La Gerche A. Defining the interaction between exercise and arrhythmogenic right ventricular cardiomyopathy. European Journal of Heart Failure. 2015; 17: 128\u2013131.","DOI":"10.1002\/ejhf.224"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Corrado D, Zorzi A. Arrhythmogenic right ventricular cardiomyopathy and sports activity. European Heart Journal. 2015; 36: 1708\u20131710.","DOI":"10.1093\/eurheartj\/ehv183"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Murray B. Arrhythmogenic right ventricular dysplasia\/cardiomyopathy (ARVD\/C): a review of molecular and clinical literature. Journal of Genetic Counseling. 2012; 21: 494\u2013504.","DOI":"10.1007\/s10897-012-9497-7"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Cerrone M, Marr\u00f3n-Li\u00f1ares GM, van Opbergen CJM, Costa S, Bourfiss M, P\u00e9rez-Hern\u00e1ndez M, et al. Role of plakophilin-2 expression on exercise-related progression of arrhythmogenic right ventricular cardiomyopathy: a translational study. European Heart Journal. 2022; 43: 1251\u20131264.","DOI":"10.1093\/eurheartj\/ehab772"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Thomas AW, Davies NA, Moir H, Watkeys L, Ruffino JS, Isa SA, et al. Exercise-associated generation of PPAR\u03b3 ligands activates PPAR\u03b3 signaling events and upregulates genes related to lipid metabolism. Journal of Applied Physiology (Bethesda, Md.: 1985). 2012; 112: 806\u2013815.","DOI":"10.1152\/japplphysiol.00864.2011"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Coscarella IL, Landim-Vieira M, Pinto JR, Chelko SP. Arrhythmogenic Cardiomyopathy: Exercise Pitfalls, Role of Connexin-43, and Moving beyond Antiarrhythmics. International Journal of Molecular Sciences. 2022; 23: 8753.","DOI":"10.3390\/ijms23158753"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013; 494: 105\u2013110.","DOI":"10.1038\/nature11799"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Chen L, Yang F, Chen X, Rao M, Zhang NN, Chen K, et al. Comprehensive Myocardial Proteogenomics Profiling Reveals C\/EBP\u03b1 as the Key Factor in the Lipid Storage of ARVC. Journal of Proteome Research. 2017; 16: 2863\u20132876.","DOI":"10.1021\/acs.jproteome.7b00165"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Takemoto Y, Tserendagva M, Uesugi M. Suppression of SREBP by a transmembrane protein mutated in cardiomyopathy. The Journal of Biological Chemistry. 2025; 301: 110644.","DOI":"10.1016\/j.jbc.2025.110644"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Sommariva E, Brambilla S, Carbucicchio C, Gambini E, Meraviglia V, Dello Russo A, et al. Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy. European Heart Journal. 2016; 37: 1835\u20131846.","DOI":"10.1093\/eurheartj\/ehv579"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Volani C, Rainer J, Hernandes VV, Meraviglia V, Pramstaller PP, Sm\u00e1rason SV, et al. Metabolic Signature of Arrhythmogenic Cardiomyopathy. Metabolites. 2021; 11: 195.","DOI":"10.3390\/metabo11040195"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Vencato S, Romanato C, Forino M, Fossati G, Velle A, Facchinello N, et al. Givinostat inhibits in vitro differentiation of cardiac fibroadipogenic precursors from a mouse model of arrhythmogenic cardiomyopathy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025; 191: 118549.","DOI":"10.1016\/j.biopha.2025.118549"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Risato G, Bra\u00f1as Casas R, Cason M, Bueno Marinas M, Pinci S, De Gaspari M, et al. In Vivo Approaches to Understand Arrhythmogenic Cardiomyopathy: Perspectives on Animal Models. Cells. 2024; 13: 1264.","DOI":"10.3390\/cells13151264"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Centner AM, Shiel EA, Farra W, Cannon EN, Landim-Vieira M, Salazar G, et al. High-Fat Diet Augments Myocardial Inflammation and Cardiac Dysfunction in Arrhythmogenic Cardiomyopathy. Nutrients. 2024; 16: 2087.","DOI":"10.3390\/nu16132087"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Lin Y, Liu R, Huang Y, Yang Z, Xian J, Huang J, et al. Reactivation of PPAR\u03b1 alleviates myocardial lipid accumulation and cardiac dysfunction by improving fatty acid \u03b2-oxidation in Dsg2-deficient arrhythmogenic cardiomyopathy. Acta Pharmaceutica Sinica. B. 2023; 13: 192\u2013203.","DOI":"10.1016\/j.apsb.2022.05.018"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Packer M. The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. Journal of the American College of Cardiology. 2025; 86: 1269\u20131373.","DOI":"10.1016\/j.jacc.2025.06.055"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Engel M, Shiel EA, Chelko SP. Basic and translational mechanisms in inflammatory arrhythmogenic cardiomyopathy. International Journal of Cardiology. 2024; 397: 131602.","DOI":"10.1016\/j.ijcard.2023.131602"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Lin YN, Ibrahim A, Marb\u00e1n E, Cingolani E. Pathogenesis of arrhythmogenic cardiomyopathy: role of inflammation. Basic Research in Cardiology. 2021; 116: 39.","DOI":"10.1007\/s00395-021-00877-5"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Ren J, Chen L, Chen X, Zhang N, Sun X, Song J. Acylation-stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy. ESC Heart Failure. 2023; 10: 492\u2013501.","DOI":"10.1002\/ehf2.14218"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Chelko SP, Asimaki A, Lowenthal J, Bueno-Beti C, Bedja D, Scalco A, et al. Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. Circulation. 2019; 140: 1491\u20131505.","DOI":"10.1161\/CIRCULATIONAHA.119.040676"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. Journal of the American College of Cardiology. 2014; 63: 2491\u20132502.","DOI":"10.1016\/j.jacc.2014.01.054"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Writing Committee Members, Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026; 153: e1154\u2013e1276.","DOI":"10.1161\/CIR.0000000000001423"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Molecular Aspects of Medicine. 2019; 65: 70\u201399.","DOI":"10.1016\/j.mam.2018.07.001"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Kadoglou NPE, Velidakis N, Khattab E, Kassimis G, Patsourakos N. The interplay between statins and adipokines. Is this another explanation of statins' 'pleiotropic' effects? Cytokine. 2021; 148: 155698.","DOI":"10.1016\/j.cyto.2021.155698"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Balakumar P, Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? British Journal of Pharmacology. 2012; 165: 373\u2013379.","DOI":"10.1111\/j.1476-5381.2011.01597.x"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Sadowitz B, Maier KG, Gahtan V. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease. Vascular and Endovascular Surgery. 2010; 44: 241\u2013251.","DOI":"10.1177\/1538574410362922"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Triglia LT, Gurgoglione FL, Barocelli F, Bianconcini M, Niccoli G. Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications. Current Medicinal Chemistry. 2025; 32: 2950\u20132970.","DOI":"10.2174\/0109298673311105240902053715"},{"key":"ref69","unstructured":"Li X, Liu X, Liu X, Du X, Kang J, L\u00fc Q, et al. Effect of statin therapy on mortality in patients with non-ischemic dilated cardiomyopathy. Zhonghua Yi Xue Za Zhi. 2010; 90: 1974\u20131977. (In Chinese)"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, Shalaby A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. Journal of the American College of Cardiology. 2006; 48: 1228\u20131233.","DOI":"10.1016\/j.jacc.2006.05.053"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Verma N, Figueredo VM. Statins in non-ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding. International Journal of Clinical Practice. 2011; 65: 1156\u20131164.","DOI":"10.1111\/j.1742-1241.2011.02753.x"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Bielecka-Dabrowa A, Mikhailidis DP, Rizzo M, von Haehling S, Rysz J, Banach M. The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up. Lipids in Health and Disease. 2013; 12: 47.","DOI":"10.1186\/1476-511X-12-47"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Domanski M, Coady S, Fleg J, Tian X, Sachdev V. Effect of Statin Therapy on Survival in Patients With Nonischemic Dilated Cardiomyopathy (from the Beta Blocker Evaluation of Survival Trial [BEST]). The American Journal of Cardiology. 2007; 99: 1448\u20131450.","DOI":"10.1016\/j.amjcard.2006.12.080"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, Poole JE, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). American Heart Journal. 2007; 153: 573\u2013578.","DOI":"10.1016\/j.ahj.2007.02.002"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Wanahita N, Chen J, Bangalore S, Shah K, Rachko M, Coleman CI, et al. The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. American Journal of Therapeutics. 2012; 19: 16\u201323.","DOI":"10.1097\/MJT.0b013e3181e9087a"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Buber J, Goldenberg I, Moss AJ, Wang PJ, McNitt S, Hall WJ, et al. Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). Journal of the American College of Cardiology. 2012; 60: 749\u2013755.","DOI":"10.1016\/j.jacc.2012.03.041"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. Journal of the American College of Cardiology. 2006; 47: 769\u2013773.","DOI":"10.1016\/j.jacc.2005.09.053"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Sommariva E, Lippi M, Bruttini F, Cannata F, Baggiano A, Schiavone M, et al. Statin effect on arrhythmogenic cardiomyopathy disease progression (SEARCH): Randomized clinical study protocol. PloS One. 2025; 20: e0332876.","DOI":"10.1371\/journal.pone.0332876"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Ferri N, Ruscica M, Fazio S, Corsini A. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. Journal of Clinical Medicine. 2024; 13: 943.","DOI":"10.3390\/jcm13040943"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Current Pharmaceutical Design. 2012; 18: 1519\u20131530.","DOI":"10.2174\/138161212799504803"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Pontremoli M, Brioschi M, Baetta R, Ghilardi S, Banfi C. Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells. Scientific Reports. 2018; 8: 16671.","DOI":"10.1038\/s41598-018-35119-7"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American Journal of Cardiovascular Drugs: Drugs, Devices, and other Interventions. 2023; 23: 477\u2013495.","DOI":"10.1007\/s40256-023-00594-5"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane Database of Systematic Reviews. 2018; 11: CD012502.","DOI":"10.1002\/14651858.CD012502.pub2"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine. 2015; 372: 2387\u20132397.","DOI":"10.1056\/NEJMoa1410489"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Sander P, Feng M, Schweitzer MK, Wilting F, Gutenthaler SM, Arduino DM, et al. Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca2+ uptake and suppress cardiac arrhythmogenesis. British Journal of Pharmacology. 2021; 178: 4518\u20134532.","DOI":"10.1111\/bph.15630"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Nodari S, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghiade M, et al. The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovascular Drugs and Therapy. 2009; 23: 5\u201315.","DOI":"10.1007\/s10557-008-6142-7"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. Journal of the American College of Cardiology. 2011; 57: 870\u2013879.","DOI":"10.1016\/j.jacc.2010.11.017"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Nutrition and Health. 2002; 16: 47\u201349.","DOI":"10.1177\/026010600201600112"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. The American Journal of Clinical Nutrition. 2000; 71: 202S\u20137S.","DOI":"10.1093\/ajcn\/71.1.202S"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Dimitrow PP, Jawien M. Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini Reviews in Medicinal Chemistry. 2009; 9: 1030\u20131039.","DOI":"10.2174\/138955709788922638"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Ali AH, Younis N, Abdallah R, Shaer F, Dakroub A, Ayoub MA, et al. Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies. Current Medicinal Chemistry. 2021; 28: 7427\u20137445.","DOI":"10.2174\/0929867328666210222092628"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: A new lipid-lowering therapy. European Journal of Pharmacology. 2020; 878: 173114.","DOI":"10.1016\/j.ejphar.2020.173114"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Jang Y, Rhee EJ, Choi SH. Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies. Endocrinology and Metabolism (Seoul, Korea). 2025; 40: 668\u2013686.","DOI":"10.3803\/EnM.2025.2691"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Capuozzo M, Ottaiano A, Cinque C, Farace S, Ferrara F. Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins. Hipertension Y Riesgo Vascular. 2025; 42: 116\u2013127.","DOI":"10.1016\/j.hipert.2024.12.002"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Xie S, Galimberti F, Olmastroni E, Carugo S, Catapano AL, Casula M, et al. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. Atherosclerosis. 2025; 408: 120420.","DOI":"10.1016\/j.atherosclerosis.2025.120420"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Ray R, Mahmood A, Chaudhry R, Masmoum MD, Talha M, Siddiqui FI, et al. The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis. Current Cardiology Reviews. 2025; 21: e1573403X345749.","DOI":"10.2174\/011573403X345749250122092324"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"N\u00e4gele MP, Raemy Y, Kreysing L, Barthelmes J, Ruschitzka F, Flammer AJ, et al. Improvement of retinal microvascular function after initiation of lipid-lowering therapy with PCSK9 inhibitors - An observational study. Journal of Clinical Lipidology. 2025; 19: 982\u2013989.","DOI":"10.1016\/j.jacl.2025.03.006"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Cavero-Redondo I, Moreno-Herraiz N, Del Saz-Lara A, Otero-Luis I, Recio-Rodriguez JI, Saz-Lara A. Effect of adding PCSK9 inhibitors to lipid-lowering interventions on arterial stiffness: A systematic review and meta-analysis. European Journal of Clinical Investigation. 2024; 54: e14269.","DOI":"10.1111\/eci.14269"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Dutka M, Zimmer K, \u0106wiertnia M, Ilczak T, Bobi\u0144ski R. The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol. Heart Failure Reviews. 2024; 29: 917\u2013937.","DOI":"10.1007\/s10741-024-10409-7"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Huang Q, Zhou Z, Xu L, Zhan P, Huang G. PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-\u03b21\/Smad3 pathway. Biochemical Pharmacology. 2024; 230: 116563.","DOI":"10.1016\/j.bcp.2024.116563"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Yu M, Tang W, Liang W, Xie B, Gao R, Ding P, et al. PCSK9 inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR\/STAT-3\/ROR-\u03b3t pathway. International Immunopharmacology. 2023; 124: 110962.","DOI":"10.1016\/j.intimp.2023.110962"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Duarte Lau F, Giugliano RP. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review. JAMA Cardiology. 2023; 8: 879\u2013887.","DOI":"10.1001\/jamacardio.2023.2402"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Ahmed AA, Mohamed SK, Nofal S, El Morsy EM, Ahmed AAE. Effect of bempedoic acid on angiotensin-II induced hypertension and vascular tissue remodelling in renal hypertensive rats through AMPK multiple signalling pathways modulation. Life Sciences. 2023; 320: 121573.","DOI":"10.1016\/j.lfs.2023.121573"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Ahmed AA, Mohamed SK, Nofal S, El Morsy EM, Ahmed AAE. Targeting the adenosine monophosphate-activated protein kinase signalling pathway by bempedoic acid attenuates Angiotensin II-induced cardiac remodelling in renovascular hypertension in rats. Life Sciences. 2023; 329: 121963.","DOI":"10.1016\/j.lfs.2023.121963"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Reddy S, Deoker A. Effects of bempedoic acid on markers of inflammation and Lp(a). Current Opinion in Cardiology. 2024; 39: 280\u2013285.","DOI":"10.1097\/HCO.0000000000001137"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Argiro A, Bui Q, Hong KN, Ammirati E, Olivotto I, Adler E. Applications of Gene Therapy in Cardiomyopathies. JACC. Heart Failure. 2024; 12: 248\u2013260.","DOI":"10.1016\/j.jchf.2023.09.015"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Mazzanti A, Kukavica D, Trancuccio A, Scilabra GG, Coppini L, Pergola V, et al. Genetics in arrhythmogenic cardiomyopathies: where are we now and where are we heading to? European Heart Journal Supplements: Journal of the European Society of Cardiology. 2025; 27: i98\u2013i102.","DOI":"10.1093\/eurheartjsupp\/suae114"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Kyriakopoulou E, Versteeg D, de Ruiter H, Perini I, Seibertz F, D\u00f6ring Y, et al. Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nature Cardiovascular Research. 2023; 2: 1262\u20131276.","DOI":"10.1038\/s44161-023-00378-9"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"van Opbergen CJM, Narayanan B, Sacramento CB, Stiles KM, Mishra V, Frenk E, et al. AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans. Circulation. Genomic and Precision Medicine. 2024; 17: e004305.","DOI":"10.1161\/CIRCGEN.123.004305"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Zou Y, Lu J, Lian Z, Jia J, Shen J, Li Q, et al. Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2025; 151: 1780\u20131796.","DOI":"10.1161\/CIRCULATIONAHA.124.072340"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Zhang J, Zanella F, Ellis MW, Bradford WH, Gutierrez-Lara EJ, Wang TM, et al. Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy. Circulation. Heart Failure. 2026; 19: e013801.","DOI":"10.1161\/CIRCHEARTFAILURE.125.013801"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Giuliodori A, Beffagna G, Marchetto G, Fornetto C, Vanzi F, Toppo S, et al. Loss of cardiac Wnt\/\u03b2-catenin signalling in desmoplakin-deficient AC8 zebrafish models is rescuable by genetic and pharmacological intervention. Cardiovascular Research. 2018; 114: 1082\u20131097.","DOI":"10.1093\/cvr\/cvy057"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Shiba M, Higo S, Kondo T, Li J, Liu L, Ikeda Y, et al. Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes. Human Molecular Genetics. 2021; 30: 1384\u20131397.","DOI":"10.1093\/hmg\/ddab127"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Zhang Z, Stroud MJ, Zhang J, Fang X, Ouyang K, Kimura K, et al. Normalization of Naxos plakoglobin levels restores cardiac function in mice. The Journal of Clinical Investigation. 2015; 125: 1708\u20131712.","DOI":"10.1172\/JCI80335"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Heckmann MB, Bauer R, Jungmann A, Winter L, Rapti K, Strucksberg KH, et al. AAV9-mediated gene transfer of desmin ameliorates cardiomyopathy in desmin-deficient mice. Gene Therapy. 2016; 23: 673\u2013679.","DOI":"10.1038\/gt.2016.40"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Ruppert T, Heckmann MB, Rapti K, Schultheis D, Jungmann A, Katus HA, et al. AAV-mediated cardiac gene transfer of wild-type desmin in mouse models for recessive desminopathies. Gene Therapy. 2019; 27: 516\u2013524.","DOI":"10.1038\/s41434-020-0147-7"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Sharma S, Sadasivan C, Yan Y, Oudit GY. Gene-based Therapies for Genetic Cardiomyopathies: Molecular Medicine for Heart Disease. The Canadian Journal of Cardiology. 2026; 42: 1018\u20131039.","DOI":"10.1016\/j.cjca.2026.01.055"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Yeh YH, Ko YS, Chan YH, Lai YJ, Chang GJ, Chang CJ, et al. Targeting PPAR-\u03b3 Reduces Fibrosis and Arrhythmogenic Remodeling in DSG2-Linked Arrhythmogenic Cardiomyopathy. Circulation. Genomic and Precision Medicine. 2026; e005434.","DOI":"10.1161\/CIRCGEN.125.005434"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023; 44: 3503\u20133626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"O'Donoghue ML, Morrow DA, Vavere AL, Kardassis D, Moura FA, Fagundes AADP Jr, et al. Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial. Nature Medicine. 2025; 31: 3553\u20133559.","DOI":"10.1038\/s41591-025-03951-w"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM51364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:06Z","timestamp":1788437886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM51364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":120,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)03674-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm51364","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"51364"}}